Results 41 to 50 of about 65,459 (255)

Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome [PDF]

, 2007
Objective: Previous studies have shown the importance of somatic mutations and arginine residues in the complementarity-determining regions (CDRs) of pathogenic anti-double-stranded DNA (anti-dsDNA) antibodies in human and murine lupus, and in studies of
Giles, I., Ioannou, Y., Isenberg, D.A., Lambrianides, A., Latchman, D.S., Manson, J.J., Mason, L., Rahman, A.   +7 more
core   +1 more source

Lupus nephritis management guidelines compared [PDF]

, 2015
In the past years, many (randomized) trials have been performed comparing the treatment strategies for lupus nephritis. In 2012, these data were incorporated in six different guidelines for treating lupus nephritis.
Bajema, IM, Bertsias, GK, Boumpas, DT, Gordon, C, Jayne, DR, Lightstone, L, Tesar, V, Wilhelmus, S   +7 more
core   +1 more source

Clinical profile of patients with lupus nephritis

Reumatismo, 2011
To the Editor Lupus nephritis is the strongest predictor of systemic lupus erythematosus (SLE) patient’s morbidity and mortality with a prevalence varying from 31 to 65% according to the studied population (1).
A.C. Schönrock, T.L. Skare
doaj   +1 more source

Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial. [PDF]

, 2019
BackgroundTreatment decision-making regarding immunosuppressive therapy is challenging for individuals with lupus. We assessed the effectiveness of a decision aid for immunosuppressive therapy in lupus nephritis.Methods and findingsIn a United States ...
Alarcón, Graciela S, Barton, Jennifer L, Caro, Brennda, Chatham, W Winn, Dall'Era, Maria, Eakin, Guy S, Fraenkel, Liana, Garcia, Salvador R, Green, Candace, Grossman, Jennifer, Hanrahan, Leslie M, Jandali, Bochra, Kimberly, Robert P, Leong, Amye L, Marrow, Laura, Meara, Alexa, Morgan, Charity J, Raymond, Sandra C, Reyes, Elyse, Rizvi, Tara, Saag, Kenneth G, Singh, Jasvinder A, Sloan, Jeffrey A, Street, Richard L, Suarez-Almazor, Maria E, Trupin, Laura, Winthrop, Kevin L, Yazdany, Jinoos   +27 more
core   +2 more sources

Delayed lupus nephritis

Annals of the Rheumatic Diseases, 2008
To describe and analyse the clinical and immunological characteristics of a large series of patients with delayed lupus nephritis (LN).A cross-sectional study was carried out. Patients with systemic lupus erythematosus (SLE) who developed renal involvement >or=5 years after the first manifestation(s) of the disease (delayed LN, n = 48) were compared ...
Varela, DC, Quintana, G, Somers, Emily C., Rojas-Villarraga, A, Espinosa, G, Hincapie, ME, McCune, WJ, Cervera, R, Anaya, JM   +8 more
openaire   +3 more sources

A Qualitative Analysis of Patient Perspectives and Preferences in Lupus Management to Guide Lupus Guidelines Development

Arthritis Care &Research, EarlyView.
Objective A patient‐centered approach for chronic disease management, including systemic lupus erythematosus (SLE), aligns treatment with patients’ values and preferences, leading to improved outcomes. This paper summarizes how patient experiences, perspectives, and priorities informed the American College of Rheumatology (ACR) 2024 Lupus Nephritis (LN)
Shivani Garg, Izzy Hartel, Lisa R. Sammaritano, Anca Askanase, Bonnie L. Bermas, Maria Dall'Era, Alí Duarte‐García, Victoria P. Werth, Brad Rovin, Reem A. Mustafa, Amy S. Turner, Bené Williams, Brian L. Ung, Hiya Bhavsar, Monique C. Gore‐Massy, Nahirannette Pulido, Natacha Guerrero, Natalie M. Smith, Wambui Machua, Linda T. Hiraki, Mary Beth Son   +20 more
wiley   +1 more source

Tratamento da nefrite lúpica.

Acta Médica Portuguesa, 2008
Systemic lupus erithematosus (SLE) is a multiorganic inflammatory disease characterized by a significant morbidity and mortality related not just to disease evolution but also to therapeutic side effects.
Carla Santos-Araújo, Manuel Pestana
doaj   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, EarlyView.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) Network investigators   +14 more
wiley   +1 more source

Addressing Economic Insecurities Can Improve Patient‐Reported Outcomes in Lupus

Arthritis Care &Research, EarlyView.
Objective Economic insecurities, such as food, housing, transportation, and financial challenges, are modifiable risk factors and influence patient‐reported outcomes (PROs) in systemic lupus erythematosus (SLE). We examined the following: (1) associations between economic insecurities and PROs, and (2) the impact of screening and addressing economic ...
Jay Patel, Tripti Singh, Meredith Ingersoll, Shelby Gomez, Amanda Weber, Sarah E. Panzer, Sancia Ferguson, Christie M. Bartels, Shivani Garg   +8 more
wiley   +1 more source

Therapeutically targeting proinflammatory type I interferons in systemic lupus erythematosus: efficacy and insufficiency with a specific focus on lupus nephritis

Frontiers in Immunology
Type I interferons (IFN-Is) are important players in the immunopathogenesis of systemic lupus erythematosus (SLE). Pathogenic events in patients with SLE are potent triggers of IFN-I induction, yet IFN-I may induce or initiate the immunopathogenesis ...
Benjamin Lai, Shue-Fen Luo, Jenn-Haung Lai, Jenn-Haung Lai   +3 more
doaj   +1 more source